Improvement of Memory and Spatial Cognitive Function by Continuous Ingestion of 100mg/day of γ—Aminobutyric Acid（GABA）―A Randomized, Double—blind, Placebo—controlled Parallel—group Clinical Trial―

Background/Objectives　As the aging population of the world is increasing, it is important to prevent cognitive decline in the elderly before they develop dementia. Previously, in a preliminary study using animal model, we found that GABA might improve cognitive function. Thus, we aimed to evaluate the effect of 100 mg of γ-aminobutyric acid（GABA）intake on cognitive function in healthy adult subjects aged ≥40 years for practical applications. Methods　This was a randomized, double -blind, placebo-controlled, parallel-group clinical trial. Thirty healthy participants each were assigned to either the placebo group or the GABA group; those in the latter group were given capsules containing 100 mg GABA daily for 12 weeks. Cognitive functions were assessed using Cognitrax and the Repeatable Battery for the Assessment of Neuropsychological Status（RBANS）test. Quality of life（QOL）was assessed using the MOS 36-Item Short Form Health Survey（SF-36）. Results　GABA improved or maintained cognitive function on the domain of Visuospatial/ Constructional and Delayed Memory in RBANS. Regarding QOL, the GABA group showed significant improvements in SF-36 domain of Physical Functioning. No adverse effects or clinically concerning changes were observed. Conclusions　These results indicate that GABA treatment appeared to safely enhance memory and spatial cognitive function in healthy adults. （UMI36726）